Association of SLC genotype with overall survival
The correlation of the SLC polymorphisms with survival in 593 lung cancer samples was investigated. After three years, 83.1% (493) of patients had died, and 16.8% (100) had survived. The association of theSLC  SNPs with lung cancer survival was investigated using both univariate and multivariate analysis after adjusting for smoking status, gender, age, tumor stage, ECOG,KPS, and histology. This analysis used four alternative models (co-dominant, dominant, recessive, and additive) to determine the relationship between SLC  polymorphism and overall survival (OS) in lung cancer patients. As demonstrated inTable 3 , the findings were presented as the best-fitted model. Lung carcinoma patients who were harboring mutant genotype (AA ) for SLC19A1 G80A polymorphism had a higher median survival time (MST) as compared to the subjects carrying wild type (GG ) genotype (MST=9.33 versus 8.23, p=0.4). TheSLC19A1 G80A polymorphism did not show any significant difference in survival in any of the models used.
For SLCO1B1 A388G , in the co-dominant model, we observed very marginal lower survival in patients carrying both mutant (GG ) alleles as compared to the patients who were carrying both wild-types(AA ) alleles (MST=7.8 versus 7.9; Log-rank p=0.41; HR=1.10). After applying the Cox regression model, results demonstrated poor survival outcomes in patients carrying mutant (GG ) alleles when compared with patients carrying wild (AA ) allele (HR=1.40, 95% I=1.0-1.97; p=0.04 ), as shown in figure 3. ForSLCO1B1 T 521C polymorphism, we observed lower survival in the lung cancer patients who had mutant genotype (CC ) as compared to the patients carrying wild-type genotype (TT ) (MST=5.16 versus 7.97; p=0.80). However, no significant differences in terms of survival were observed for the SLCO1B1 T521C variant.
For the SLCO1B3 A1683-5676G variant, the patients having heterozygous allele (AG ) showed lower median survival in lung carcinoma patients as compared to the individuals harboring wild type (AA ) genotype (MST=7.6 versus 7.97; p=0.58). However, only one patient harbored mutant genotype, so the survival differences were not calculated for this group. None of the other models showed any prognostic significance forA1683-5676G polymorphism for overall survival in lung cancer patients.